AIM To assess the efficacy and safety of intravenous immunoglobulin (IVIg) for patients with Alzheimer's disease (AD). MATERIALS AND METHODS We searched electronic databases and other sources for randomized controlled trials comparing IVIg with placebo or other treatment for adults with AD. Primary outcome was change from baseline in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog). RESULTS Five placebo-controlled trials were included in the meta-analysis. Compared to placebo, IVIg 0.2 and 0.4 g/kg once every two weeks did not change ADAS-Cog score (weighted mean difference: 0.37, 95% confidence interval: -1.46 to 2.20 and 0.77, -1.34 to 2.88, respectively). Furthermore, except for an increase in the incidence of rash, IVIg did not affect the incidence of other adverse events. CONCLUSION IVIg, albeit safe, is inefficacious for treatment of patients with AD. Future trials targeting earlier stages of disease or applying different dosing regimens may be warranted to clarify its therapeutic potential.

中文翻译：

---

阿尔茨海默氏病患者的静脉免疫球蛋白：系统评价和荟萃分析。

目的评估静脉注射免疫球蛋白（IVIg）对阿尔茨海默氏病（AD）患者的疗效和安全性。材料和方法我们在电子数据库和其他来源中搜索了IVIg与安慰剂或其他成人AD治疗方法进行比较的随机对照试验。主要结果是阿尔茨海默病疾病评估量表-认知子量表（ADAS-Cog）的基线变化。结果荟萃分析包括五项安慰剂对照试验。与安慰剂相比，每两周一次IVIg 0.2和0.4 g / kg不会改变ADAS-Cog评分（加权平均差异：0.37，95％置信区间：分别为-1.46至2.20和0.77，-1.34至2.88）。此外，除了皮疹的发生率增加外，IVIg不会影响其他不良事件的发生率。结论尽管很安全，对AD患者的治疗无效。可能需要针对疾病的早期阶段或应用不同剂量方案的未来试验来阐明其治疗潜力。